Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
about
What is the functional role of the thalidomide binding protein cereblon?Monoclonal antibodies targeting CD38 in hematological malignancies and beyondThe Role of Immunotherapy in Multiple MyelomaPotential role of daratumumab in the treatment of multiple myelomaCurrent and emerging treatment options for patients with relapsed myelomaPomalidomide for the treatment of multiple myelomaUse of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in KoreaMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementTargeted therapy for HM1.24 (CD317) on multiple myeloma cellsDevelopment of Novel Immunotherapies for Multiple MyelomaNovel therapeutic strategies for multiple myelomaCompartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune functionWhat does it take to synergistically combine sub-potent natural products into drug-level potent combinations?Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitorsRenal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma."Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaRecent advances in antimultiple myeloma drug development.A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trialManaging patients with myelofibrosis and low platelet counts.Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaEfficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-AnalysisAdverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myelomaExpression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma.Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agentsBone disease in multiple myeloma: pathophysiology and management.Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Macrophages in multiple myeloma: emerging concepts and therapeutic implications.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.Ribosomopathies: mechanisms of disease.Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogsEvidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.
P2860
Q24635072-246862B8-C4FA-470A-B203-1AFB3696B447Q26766718-62349312-0797-4002-BB52-C56C04D52132Q26771144-8C47B731-B4B9-444B-885D-912DBF6DE2B2Q26824157-D7DA4C97-AAA4-466D-B6D5-D5E1903F5365Q26830878-1449A3AC-BA56-4C3C-A6B0-E7C5DADCD123Q26859133-3DA55CC8-0D47-477D-B01A-6A11B779B47BQ26992002-6E816D32-C18A-4959-820E-E2F6DB45875CQ26998884-87D79428-15DB-4FF2-BDA7-EAEE864025D6Q27026161-50D74B5D-B37F-4AA1-A964-86B1738AF889Q28066890-C1C5B6CE-3AB6-452A-A85F-899D0C1BE440Q28081590-F16BDF70-266B-4AC3-8820-0E1563B3CFCAQ28383385-BA6577F9-58E7-43AF-99A6-AF1ACFF48FCCQ28485360-390F32ED-7981-4143-9294-F2A32AC012B7Q28537997-44EE3100-2799-43A8-835E-0130952FE9CFQ30275870-99E1EDDF-30D2-4018-83E9-341AE330AE06Q30657752-753545BA-32B1-4044-9608-95591061608DQ30802505-D893F9A8-9F58-4435-A3DD-0807AD7CEA9CQ33403183-CB193522-2945-4B1C-A5B7-1C55B78507D2Q33413142-A936CA3E-FE93-4D97-96F4-166128DD371BQ33416297-E8C38B52-A67C-471F-B405-A7DF68A13BD9Q33431621-D6D6E4A9-3AFE-4AB5-B9DE-6ADF0E3F1B71Q33432406-3C9111CD-9D8E-458D-97C0-2C93DDCA8BBAQ33432492-BA49ED6D-40AF-4EAA-AEFD-0C67179E2DF0Q33436627-AB683D5D-6CC6-4B14-AA68-6E69F633E462Q33441845-8EE5506F-6749-4A46-8891-ECD7F5496FABQ33442923-B0B37EAD-EC5E-4A16-B556-F31B5676A833Q33443411-3B1D7E58-299E-4F46-B9E6-CCDBAFEFEFE6Q33816012-400D5769-13C1-444C-B94C-CADB6B72BB29Q33846806-A92EC842-F4B0-4B86-BC52-771B6A0480A5Q33880085-052B0B7A-F816-486B-9E7C-017D1307F318Q33886073-02F62AEA-705A-4BB8-9789-9AE02EAE2BDDQ34045789-8D980A89-7B97-4F7F-858F-9D702D35478EQ34210005-117225AE-6942-494C-AF66-EB47599A2079Q34220013-55524B75-A8D0-4794-AE08-F165D7B7B26CQ34329242-B37D2B26-B957-4F1E-AFFB-939F24BF125BQ34380489-11ACB3A6-5431-41BE-A0A6-563018F2B070Q34447864-B98388DB-343D-46DB-8DE5-A65A0E7A7FBCQ34454066-CBC3EBC0-1DC3-4868-B3FA-6C7BE2E30EC9Q34661167-F063577D-4DFB-461F-BAD4-36B5DECAA772Q34719436-6F695579-6F0A-4668-BB39-97EAFDCFECFF
P2860
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
@ast
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
@en
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
@nl
type
label
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
@ast
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
@en
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
@nl
prefLabel
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
@ast
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
@en
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
@en
P2093
P2860
P2888
P3181
P356
10.1038/LEU.2009.236
P407
P577
2009-11-12T00:00:00Z
P6179
1026282357